Inflammasome and cytokine blocking strategies in autoinflammatory disorders.

[1]  G. Kilic,et al.  Efficacy and Safety of Biologic Treatments in Familial Mediterranean Fever , 2013, The American journal of the medical sciences.

[2]  G. Yancopoulos,et al.  Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. , 2013, Rheumatology.

[3]  C. Wouters,et al.  FRI0328 Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): 2-year data from tender, a phase 3 clinical trial , 2013 .

[4]  L. Obici,et al.  THU0396 Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome (TRAPS) , 2013 .

[5]  Z. Amoura,et al.  Anakinra in Adult‐Onset Still's Disease: Long‐Term Treatment in Patients Resistant to Conventional Therapy , 2013, Arthritis care & research.

[6]  L. Schnitzler,et al.  Schnitzler's syndrome: diagnosis, treatment, and follow‐up , 2013, Allergy.

[7]  D. Knockaert,et al.  Canakinumab in Schnitzler syndrome. , 2013, Seminars in arthritis and rheumatism.

[8]  V. Pascual,et al.  Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. , 2013, Arthritis and rheumatism.

[9]  C. Wouters,et al.  Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. , 2012, The New England journal of medicine.

[10]  P. Richette,et al.  Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. , 2012, Joint, bone, spine : revue du rhumatisme.

[11]  A. Rissanen,et al.  Effect of anti‐IL‐1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo‐controlled trial , 2012, Diabetes, obesity & metabolism.

[12]  M. Dougados,et al.  Rituximab Treatment for Spondyloarthritis. A Nationwide Series: Data from the AIR Registry of the French Society of Rheumatology , 2012, The Journal of Rheumatology.

[13]  M. Gattorno,et al.  Biologic drugs in autoinflammatory syndromes. , 2012, Autoimmunity reviews.

[14]  F. Iacoponi,et al.  The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature. , 2012, Autoimmunity reviews.

[15]  M. Gahr,et al.  Anakinra: A safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA) , 2012, Rheumatology International.

[16]  A. Feily,et al.  An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. , 2012, Current clinical pharmacology.

[17]  K. Minden,et al.  Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement , 2012, Arthritis Research & Therapy.

[18]  M. Weisman,et al.  Rilonacept for Colchicine-Resistant or -Intolerant Familial Mediterranean Fever , 2012, Annals of Internal Medicine.

[19]  Y. Soo,et al.  Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. , 2012, Clinical therapeutics.

[20]  James I. Clower,et al.  Rilonacept (interleukin‐1 trap) for prevention of gout flares during initiation of uric acid–lowering therapy: Results from a phase III randomized, double‐blind, placebo‐controlled, confirmatory efficacy study , 2012, Arthritis care & research.

[21]  H. Kautiainen,et al.  Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still’s Disease. An Open, Randomized, Multicenter Study , 2012, The Journal of Rheumatology.

[22]  P. Efthimiou,et al.  The use of Canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease. , 2012, Seminars in arthritis and rheumatism.

[23]  B. Bader-Meunier,et al.  Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. , 2012, Rheumatology.

[24]  L. Obici,et al.  Efficacy and Safety of Canakinumab in Patients with TNF Receptor Associated Periodic Syndrome , 2012 .

[25]  O. Silvennoinen,et al.  JAK Kinases in Health and Disease: An Update , 2012, The open rheumatology journal.

[26]  L. Joosten,et al.  Inflammation links excess fat to insulin resistance: the role of the interleukin‐1 family , 2012, Immunological reviews.

[27]  M. Dougados,et al.  Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. , 2012, Rheumatology.

[28]  N. Shao,et al.  Oxidized low-density lipoprotein induces secretion of interleukin-1β by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation. , 2012, Biochemical and biophysical research communications.

[29]  B. Koller,et al.  NLRP1-Dependent Pyroptosis Leads to Acute Lung Injury and Morbidity in Mice , 2012, The Journal of Immunology.

[30]  J. Braun,et al.  One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare , 2012, Annals of the rheumatic diseases.

[31]  J. O’Shea,et al.  Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. , 2012, Current opinion in pharmacology.

[32]  D. Kastner,et al.  Lighting the fires within: the cell biology of autoinflammatory diseases , 2012, Nature Reviews Immunology.

[33]  M. Donath,et al.  Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes , 2012, Diabetes Care.

[34]  P. Tak,et al.  Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory? , 2012, Current opinion in rheumatology.

[35]  T. Volz,et al.  Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome. , 2012, Acta dermato-venereologica.

[36]  M. Galeazzi,et al.  A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra. , 2012, Clinical and experimental rheumatology.

[37]  S. Paul,et al.  Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. , 2012, Arthritis and rheumatism.

[38]  T. Zuberbier,et al.  Efficacy and safety of the interleukin‐1 antagonist rilonacept in Schnitzler syndrome: an open‐label study , 2012, Allergy.

[39]  S. Özen,et al.  Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review , 2012, Annals of the rheumatic diseases.

[40]  R. Cimaz,et al.  Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. , 2012, Annals of internal medicine.

[41]  S. Plontke,et al.  Progressive familial hearing loss in Muckle-Wells syndrome , 2012, Acta oto-laryngologica.

[42]  J. Cush,et al.  IL-1 Trap rilonacept in refractory adult onset Still's disease , 2012, Annals of the rheumatic diseases.

[43]  S. Holland,et al.  Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). , 2012, Arthritis and rheumatism.

[44]  G. Schett,et al.  Adult-onset Still’s disease and chronic recurrent multifocal osteomyelitis: a hitherto undescribed manifestation of autoinflammation , 2012, Rheumatology International.

[45]  M. Uffmann,et al.  Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra—case report and review , 2012, Rheumatology International.

[46]  G. Hatemi,et al.  Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye disease , 2012, Annals of the rheumatic diseases.

[47]  H. Schumacher,et al.  Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions , 2012, Annals of the rheumatic diseases.

[48]  M. Borri,et al.  Successful use of canakinumab in a patient with resistant Behçet's disease. , 2012, Clinical and experimental rheumatology.

[49]  I. Ben-Zvi,et al.  The Israeli Annual FMF, Amyloidosis and Other Autoinflammatory Diseases Meeting (July 2011): a bridge spanning these entities. , 2012, The Israel Medical Association journal : IMAJ.

[50]  K. Thomas,et al.  Deficiency of interleukin-1-receptor antagonist syndrome: a rare auto-inflammatory condition that mimics multiple classic radiographic findings , 2012, Pediatric Radiology.

[51]  R. Terkeltaub,et al.  Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. , 2012, Arthritis and rheumatism.

[52]  L. Franchi,et al.  Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes , 2012, Clinical and experimental immunology.

[53]  G. Burmester,et al.  Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial , 2012, Annals of the rheumatic diseases.

[54]  D. Kastner,et al.  Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. , 2012, Arthritis and rheumatism.

[55]  A. Paller,et al.  Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. , 2012, Arthritis and rheumatism.

[56]  P. Ferguson,et al.  Current Understanding of the Pathogenesis and Management of Chronic Recurrent Multifocal Osteomyelitis , 2012, Current Rheumatology Reports.

[57]  I. Rosner,et al.  Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases. , 2012, Best practice & research. Clinical rheumatology.

[58]  N. Wulffraat,et al.  A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. , 2012, Arthritis and rheumatism.

[59]  Santanu Bose,et al.  TLR2/MyD88/NF-κB Pathway, Reactive Oxygen Species, Potassium Efflux Activates NLRP3/ASC Inflammasome during Respiratory Syncytial Virus Infection , 2012, PloS one.

[60]  M. McDermott,et al.  Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases , 2012, Current opinion in rheumatology.

[61]  L. Espinoza,et al.  Psoriatic Arthritis: Radiographic Joint Repair Following Etanercept Therapy , 2012, The Journal of Rheumatology.

[62]  P. Hawkins,et al.  Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study , 2011, Arthritis research & therapy.

[63]  Kevin R. Dufendach,et al.  The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. , 2011, Arthritis and rheumatism.

[64]  A. Mirza,et al.  Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study , 2011, Annals of the rheumatic diseases.

[65]  O. Ohara,et al.  High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. , 2011, Arthritis and rheumatism.

[66]  P. Libby,et al.  Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.

[67]  F. Retornaz,et al.  Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. , 2011, Seminars in arthritis and rheumatism.

[68]  Hao Xu,et al.  The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus , 2011, Nature.

[69]  A. Martini,et al.  Long-term follow-up of systemic onset juvenile idiopathic arthritis patients treated with Anakinra , 2011, Pediatric Rheumatology Online Journal.

[70]  P. Ferguson,et al.  Novel mutation of the LPIN2 gene in Turkish brothers with Majeed syndrome. Response to IL-1 inhibition , 2011, Pediatric Rheumatology Online Journal.

[71]  M. Simpson,et al.  Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. , 2011, American journal of human genetics.

[72]  I. Olivieri,et al.  Etanercept in spondyloarthropathies. Part I: current evidence of efficacy. , 2011, Clinical and experimental rheumatology.

[73]  Matthias Schneider,et al.  Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. , 2011, Rheumatology.

[74]  J. Drenth,et al.  On-demand anakinra treatment is effective in mevalonate kinase deficiency , 2011, Annals of the rheumatic diseases.

[75]  P. Hawkins,et al.  Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes , 2011, Annals of the rheumatic diseases.

[76]  A. Smahi,et al.  Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. , 2011, The New England journal of medicine.

[77]  D. Kastner,et al.  Genetics of monogenic autoinflammatory diseases: past successes, future challenges , 2011, Nature Reviews Rheumatology.

[78]  Anna K Rieger,et al.  Cutting Edge: Reactive Oxygen Species Inhibitors Block Priming, but Not Activation, of the NLRP3 Inflammasome , 2011, The Journal of Immunology.

[79]  H. Hoffman,et al.  Autoinflammation: translating mechanism to therapy , 2011, Journal of leukocyte biology.

[80]  Sheng Wei,et al.  Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. , 2011, International immunopharmacology.

[81]  P. Jégo,et al.  Mevalonate Kinase Deficiency: A Survey of 50 Patients , 2011, Pediatrics.

[82]  S. Amselem,et al.  Role of interleukin-1β in NLRP12-associated autoinflammatory disorders and resistance to anti-interleukin-1 therapy. , 2011, Arthritis and rheumatism.

[83]  A. Tzioufas,et al.  Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study , 2011, Arthritis research & therapy.

[84]  D. Kastner,et al.  Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1β activation and severe autoinflammation in mice. , 2011, Immunity.

[85]  K. Mills,et al.  Caspase-1–Processed Cytokines IL-1β and IL-18 Promote IL-17 Production by γδ and CD4 T Cells That Mediate Autoimmunity , 2011, The Journal of Immunology.

[86]  S. Masters,et al.  Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. , 2011, Trends in molecular medicine.

[87]  L. Joosten,et al.  Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. , 2011, The Journal of clinical endocrinology and metabolism.

[88]  D. Kastner,et al.  Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade , 2011, Proceedings of the National Academy of Sciences.

[89]  P. Tighe,et al.  Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. , 2011, Arthritis and rheumatism.

[90]  D. Gladman,et al.  Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. , 2011, Arthritis and rheumatism.

[91]  Yoshiya Tanaka,et al.  Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet’s disease , 2011, Modern rheumatology.

[92]  A. So,et al.  Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study , 2011, Arthritis Research & Therapy.

[93]  M. Nazarinia,et al.  Infliximab for patients with neuro-Behcet's disease: case series and literature review , 2011, Clinical Rheumatology.

[94]  J. Braun,et al.  Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study , 2011, Annals of the rheumatic diseases.

[95]  Daniel L. Kastner,et al.  Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS) , 2011, The Journal of experimental medicine.

[96]  M. McDermott,et al.  Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome , 2011, Annals of the rheumatic diseases.

[97]  S. Özen,et al.  Anti-Interleukin 1 Treatment for Patients with Familial Mediterranean Fever Resistant to Colchicine , 2011, The Journal of Rheumatology.

[98]  J. Tschopp,et al.  Cutting Edge: Cyclic Polypeptide and Aminoglycoside Antibiotics Trigger IL-1β Secretion by Activating the NLRP3 Inflammasome , 2011, The Journal of Immunology.

[99]  P. Sfikakis,et al.  A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study. , 2011, Rheumatology.

[100]  A. Martini,et al.  Clinical Presentation and Pathogenesis of Cold-Induced Autoinflammatory Disease in a Family With Recurrence of an NLRP12 Mutation , 2011, Arthritis and rheumatism.

[101]  D. Foell,et al.  Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. , 2011, Arthritis and rheumatism.

[102]  A. Oikonomou,et al.  The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis , 2011, Annals of the rheumatic diseases.

[103]  D. Kastner,et al.  Autoinflammation in 2010: Expanding clinical spectrum and broadening therapeutic horizons , 2011, Nature Reviews Rheumatology.

[104]  A. Chakraborty,et al.  Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS) , 2011, Arthritis Research & Therapy.

[105]  P. Hawkins,et al.  The emerging role of interleukin-1β in autoinflammatory diseases. , 2011, Arthritis and rheumatism.

[106]  Andrew I. Shulman,et al.  Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. , 2011, Arthritis and rheumatism.

[107]  George Kollias,et al.  Blockade of TNF-α rapidly inhibits pain responses in the central nervous system , 2011, Proceedings of the National Academy of Sciences.

[108]  John Corbin,et al.  XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases , 2011, mAbs.

[109]  A. Plebani,et al.  Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis , 2010, Annals of the rheumatic diseases.

[110]  D. Lipsker.  The Schnitzler syndrome , 2010, Orphanet journal of rare diseases.

[111]  A. Martini,et al.  Treatment of autoinflammatory syndromes , 2010, Current opinion in pediatrics.

[112]  G. Cocco,et al.  Colchicine in clinical medicine. A guide for internists. , 2010, European journal of internal medicine.

[113]  Chi-Chen Lin,et al.  Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease. , 2010, Rheumatology.

[114]  Koichiro Nakamura,et al.  Behçet's Disease (Adamantiades-Behçet's Disease) , 2010, Clinical & developmental immunology.

[115]  A. Petrie,et al.  Antibodies to human serum amyloid P component eliminate visceral amyloid deposits , 2010, Nature.

[116]  A. So,et al.  Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. , 2010, Arthritis and rheumatism.

[117]  Christine E. Becker,et al.  Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes , 2010, Nature Immunology.

[118]  T. Shaver,et al.  Clinical efficacy of etanercept for treatment of PAPA syndrome. , 2010, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[119]  R. Goldbach-Mansky,et al.  Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis , 2010, Current opinion in rheumatology.

[120]  N. Sebire,et al.  Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. , 2010, Rheumatology.

[121]  A. Martini,et al.  Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. , 2010, The Journal of pediatrics.

[122]  F. Di Virgilio,et al.  Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. , 2010, Rheumatology.

[123]  G. Vaiopoulos,et al.  Etiopathogenesis of Behçet's disease with emphasison the role of immunological aberrations , 2010, Clinical Rheumatology.

[124]  D. Kastner,et al.  Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome , 2010, Proceedings of the National Academy of Sciences.

[125]  R. Goldbach-Mansky,et al.  Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals. , 2010, Clinical immunology.

[126]  J. Braun,et al.  Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. , 2010, Arthritis and rheumatism.

[127]  L. Ginsberg,et al.  Neurologic manifestations of the cryopyrin-associated periodic syndrome , 2010, Neurology.

[128]  K. Maedler,et al.  XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model. , 2010, Endocrinology.

[129]  Eva Szomolanyi-Tsuda,et al.  The AIM2 inflammasome is essential for host-defense against cytosolic bacteria and DNA viruses , 2010, Nature Immunology.

[130]  D. Kastner,et al.  Autoinflammatory Disease Reloaded: A Clinical Perspective , 2010, Cell.

[131]  K. Moore,et al.  NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease , 2010, Nature.

[132]  S. Crovella,et al.  The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency , 2010, European Journal of Human Genetics.

[133]  Chan Zhao,et al.  [The short-term efficacy and safety treatment study of recurrent uveitis in Behcet disease with etanercept]. , 2010, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology.

[134]  U. Mrowietz,et al.  Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome. , 2010, The Journal of allergy and clinical immunology.

[135]  M. García-Carrasco,et al.  Etiopathogenesis of Behcet's disease. , 2010, Autoimmunity reviews.

[136]  M. Dougados,et al.  Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry , 2010, Annals of the rheumatic diseases.

[137]  U. Broeckel,et al.  An autoinflammatory disease due to homozygous deletion of the IL1RN locus. , 2009, The New England journal of medicine.

[138]  P. Hawkins,et al.  Use of canakinumab in the cryopyrin-associated periodic syndrome. , 2009, The New England journal of medicine.

[139]  D. Kastner,et al.  Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. , 2009, The Journal of allergy and clinical immunology.

[140]  T. Ruzicka,et al.  Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin‐1 receptor antagonist anakinra , 2009, The British journal of dermatology.

[141]  Denis Gris,et al.  Staphylococcus aureus α-Hemolysin Activates the NLRP3-Inflammasome in Human and Mouse Monocytic Cells , 2009, PloS one.

[142]  R. Terkeltaub,et al.  The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study , 2009, Annals of the rheumatic diseases.

[143]  G. Núñez,et al.  Cutting Edge: TNF-α Mediates Sensitization to ATP and Silica via the NLRP3 Inflammasome in the Absence of Microbial Stimulation1 , 2009, The Journal of Immunology.

[144]  E. Alnemri,et al.  Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression1 , 2009, The Journal of Immunology.

[145]  C. Gabay,et al.  Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. , 2009, Joint, bone, spine : revue du rhumatisme.

[146]  P. Gregersen,et al.  An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. , 2009, The New England journal of medicine.

[147]  J. Soep,et al.  Anakinra for Systemic Juvenile Arthritis: The Rocky Mountain Experience , 2009, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[148]  A. Simon,et al.  Recurrent febrile syndromes—what a rheumatologist needs to know , 2009, Nature Reviews Rheumatology.

[149]  C. Cerquaglia,et al.  Familial Mediterranean Fever: a review for clinical management. , 2009, Joint, bone, spine : revue du rhumatisme.

[150]  H. Hoffman.  Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS) , 2009 .

[151]  Seth L Masters,et al.  Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). , 2009, Annual review of immunology.

[152]  F. Martinon,et al.  The inflammasomes: guardians of the body. , 2009, Annual review of immunology.

[153]  J. Rosenbaum,et al.  The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity. , 2009, Arthritis and rheumatism.

[154]  G. Hitman,et al.  Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. , 2009, Arthritis and rheumatism.

[155]  Daniel R. Caffrey,et al.  AIM2 recognizes cytosolic dsDNA and forms a caspase-1 activating inflammasome with ASC , 2009, Nature.

[156]  I. Mitroulis,et al.  Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. , 2008, The Netherlands journal of medicine.

[157]  L. Devlin,et al.  A rare cause of a common symptom, Anakinra is effective in the urticaria of Schnitzler Syndrome: a case report , 2008, Cases journal.

[158]  G. Pohl,et al.  Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[159]  J. Drenth,et al.  Long-Term Follow-Up, Clinical Features, and Quality of Life in a Series of 103 Patients With Hyperimmunoglobulinemia D Syndrome , 2008, Medicine.

[160]  R. Goldbach-Mansky,et al.  The spectrum of monogenic autoinflammatory syndromes: Understanding disease mechanisms and use of targeted therapies , 2008, Current allergy and asthma reports.

[161]  L. Punzi,et al.  Resistant Behçet disease responsive to anakinra. , 2008, Annals of internal medicine.

[162]  K. Rock,et al.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization , 2008, Nature Immunology.

[163]  G. Yancopoulos,et al.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. , 2008, Arthritis and rheumatism.

[164]  D. Kastner,et al.  A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. , 2008, Arthritis and rheumatism.

[165]  K. Moore,et al.  The NALP3 inflammasome is involved in the innate immune response to amyloid-β , 2008, Nature Immunology.

[166]  R. Roldán,et al.  Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. , 2008, Joint, bone, spine : revue du rhumatisme.

[167]  P. Frischmeyer-Guerrerio,et al.  Remission of Schnitzler syndrome after treatment with anakinra. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[168]  H. Waterham,et al.  Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up , 2008, Clinical Rheumatology.

[169]  A. Martini,et al.  The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. , 2008, Arthritis and rheumatism.

[170]  A. Plebani,et al.  Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. , 2008, Arthritis and rheumatism.

[171]  B. Stych,et al.  Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives* , 2008, Current medical research and opinion.

[172]  J. B. Oliveira,et al.  TNF receptor-associated periodic syndrome (TRAPS): Description of a novel TNFRSF1A mutation and response to etanercept , 2008, European Journal of Pediatrics.

[173]  H. Waterham,et al.  Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1. , 2008, Molecular immunology.

[174]  C. Cerquaglia,et al.  Efficacy of etanercept in the treatment of a patient with Behçet’s disease , 2008, Clinical Rheumatology.

[175]  N. Sepp,et al.  Successful use of anakinra to treat refractory Schnitzler's syndrome. , 2008, Clinical and experimental rheumatology.

[176]  S. Marlin,et al.  Mutations in NALP12 cause hereditary periodic fever syndromes , 2008, Proceedings of the National Academy of Sciences.

[177]  P. Emery,et al.  Successful treatment of resistant pseudogout with anakinra. , 2008, Arthritis and rheumatism.

[178]  L. Cuisset,et al.  Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. , 2008, The Journal of rheumatology.

[179]  M. Donath,et al.  Cytokines and β-Cell Biology: from Concept to Clinical Translation , 2008 .

[180]  P. Hawkins,et al.  Use of Anakinra (Kineret) in the Treatment of Familial Cold Autoinflammatory Syndrome with a 16-Month Follow-Up , 2008, Journal of cutaneous medicine and surgery.

[181]  A. Ramanan,et al.  Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). , 2007, Rheumatology.

[182]  A. Farkas,et al.  Detecting DNA: getting and begetting cancer. , 2007, Current opinion in investigational drugs.

[183]  L. Kanz,et al.  Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. , 2007, Seminars in arthritis and rheumatism.

[184]  J. V. D. van der Meer,et al.  Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. , 2007, Seminars in arthritis and rheumatism.

[185]  E. Drewe,et al.  Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). , 2007, Rheumatology.

[186]  R. Misra,et al.  Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. , 2007, The Journal of rheumatology.

[187]  R. Dhôte,et al.  Treatment of Schnitzler's syndrome with anakinra. , 2007, Clinical and experimental rheumatology.

[188]  J. Yagüe,et al.  NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. , 2007, Arthritis and rheumatism.

[189]  W. Graninger,et al.  Anakinra in two adolescent female patients suffering from colchicine‐resistant familial Mediterranean fever: effective but risky , 2007, European journal of clinical investigation.

[190]  J. Sibilia,et al.  Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France , 2007, Annals of the rheumatic diseases.

[191]  J. Frenkel,et al.  Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra , 2007, Annals of the rheumatic diseases.

[192]  G. Dubyak,et al.  Nonclassical IL-1β Secretion Stimulated by P2X7 Receptors Is Dependent on Inflammasome Activation and Correlated with Exosome Release in Murine Macrophages1 , 2007, The Journal of Immunology.

[193]  I. Kreiselmaier,et al.  Schnitzler syndrome: treatment failure to rituximab but response to anakinra. , 2007, Journal of the American Academy of Dermatology.

[194]  C. Dodé,et al.  Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS). , 2007, Rheumatology.

[195]  G. Dubyak,et al.  Differential Requirement of P2X7 Receptor and Intracellular K+ for Caspase-1 Activation Induced by Intracellular and Extracellular Bacteria* , 2007, Journal of Biological Chemistry.

[196]  A. Ventura,et al.  The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever , 2007, European Journal of Pediatrics.

[197]  Caroline A Sabin,et al.  Natural history and outcome in systemic AA amyloidosis. , 2007, The New England journal of medicine.

[198]  G. Kalliolias,et al.  Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial , 2007, Annals of the rheumatic diseases.

[199]  F. Martinon,et al.  A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses , 2007, Nature Immunology.

[200]  T. Luger,et al.  Prompt response of refractory Schnitzler syndrome to treatment with anakinra. , 2007, Journal of the American Academy of Dermatology.

[201]  Allan Vaag,et al.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.

[202]  J. Tschopp,et al.  A pilot study of IL-1 inhibition by anakinra in acute gout , 2007, Arthritis research & therapy.

[203]  P. Ferguson,et al.  A splice site mutation confirms the role of LPIN2 in Majeed syndrome. , 2007, Arthritis and rheumatism.

[204]  M. Pillinger,et al.  Familial Mediterranean fever successfully treated with etanercept. , 2007, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[205]  D. Haffner,et al.  Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus Statement , 2007, Pediatrics.

[206]  K. Kersse,et al.  Inflammatory caspases: targets for novel therapies. , 2007, Current pharmaceutical design.

[207]  J. McGrath,et al.  Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. , 2006, Archives of dermatology.

[208]  J. Sarles,et al.  Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis , 2006, Journal of Inherited Metabolic Disease.

[209]  H. Waterham,et al.  A role for geranylgeranylation in interleukin‐1β secretion , 2006 .

[210]  C. Wouters,et al.  Pediatric granulomatous arthritis: an international registry. , 2006, Arthritis and rheumatism.

[211]  J. Tschopp,et al.  Caspase-1 Activation of Lipid Metabolic Pathways in Response to Bacterial Pore-Forming Toxins Promotes Cell Survival , 2006, Cell.

[212]  H. Yazıcı,et al.  Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. , 2006, Clinical and experimental rheumatology.

[213]  S. Holland,et al.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. , 2006, The New England journal of medicine.

[214]  Dennis McGonagle,et al.  A Proposed Classification of the Immunological Diseases , 2006, PLoS medicine.

[215]  P. Tighe,et al.  Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. , 2006, Arthritis and rheumatism.

[216]  D. Rigante,et al.  Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome , 2006, Rheumatology International.

[217]  M. Horton,et al.  Hyaluronan Fragments Act as an Endogenous Danger Signal by Engaging TLR21 , 2006, The Journal of Immunology.

[218]  Brian J. Smith,et al.  The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[219]  J. Malley,et al.  Cytokine profile in PFAPA syndrome suggests continuous inflammation and reduced anti-inflammatory response. , 2006, European cytokine network.

[220]  J. Boeynaems,et al.  Modulation of inflammation by extracellular nucleotides. , 2006, The Journal of investigative dermatology.

[221]  L. Cuisset,et al.  Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. , 2006, Arthritis and rheumatism.

[222]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[223]  R. Ravazzolo,et al.  Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. , 2006, Arthritis and rheumatism.

[224]  E. Alnemri,et al.  Cryopyrin and pyrin activate caspase-1, but not NF-κB, via ASC oligomerization , 2006, Cell Death and Differentiation.

[225]  S. Ozgoçmen,et al.  Familial Mediterranean fever responds well to infliximab: single case experience , 2006, Clinical Rheumatology.

[226]  A. Reiff.  The use of anakinra in juvenile arthritis , 2005, Current rheumatology reports.

[227]  K. Beaumont,et al.  IL-Converting Enzyme/Caspase-1 Inhibitor VX-765 Blocks the Hypersensitive Response to an Inflammatory Stimulus in Monocytes from Familial Cold Autoinflammatory Syndrome Patients , 2005, The Journal of Immunology.

[228]  H. D. Koning,et al.  Beneficial response to anakinra and thalidomide in Schnitzler’s syndrome , 2005, Annals of the rheumatic diseases.

[229]  R. Blanco,et al.  Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. , 2005, Arthritis and rheumatism.

[230]  C. Dinarello,et al.  Rapid responses to anakinra in patients with refractory adult-onset Still's disease. , 2005, Arthritis and rheumatism.

[231]  V. Pascual,et al.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade , 2005, The Journal of experimental medicine.

[232]  V. Pascual,et al.  Dramatic Improvement of Pyoderma Gangrenosum with Infliximab in a Patient with PAPA Syndrome , 2005, Pediatric dermatology.

[233]  H. Zeidler,et al.  Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. , 2005, Rheumatology.

[234]  N. Wulffraat,et al.  Anakinra for flares of pyogenic arthritis in PAPA syndrome. , 2005, Rheumatology.

[235]  P. Woo,et al.  Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. , 2005, Arthritis and rheumatism.

[236]  B. Goker,et al.  Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. , 2005, Arthritis and rheumatism.

[237]  J. Yagüe,et al.  Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response , 2005, European Journal of Pediatrics.

[238]  G. Firestein,et al.  Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist , 2004, The Lancet.

[239]  A. Ventura,et al.  Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever. , 2004, Clinical and experimental rheumatology.

[240]  E. Drewe,et al.  Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. , 2004, Rheumatology.

[241]  J. Verbsky,et al.  Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. , 2004, The Journal of rheumatology.

[242]  A. Utani,et al.  Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. , 2004, Blood.

[243]  T. Hsieh,et al.  Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still’s disease , 2004, Annals of the rheumatic diseases.

[244]  M. Gahr,et al.  Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients – expanding phenotype of CIAS1 related autoinflammatory syndrome , 2004, European journal of haematology.

[245]  P. Tighe,et al.  Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types. , 2004, Arthritis and rheumatism.

[246]  B. Henderson,et al.  Stress cytokines: pivotal proteins in immune regulatory networks; Opinion. , 2004, Current opinion in immunology.

[247]  J. Drenth,et al.  Beneficial response to interleukin 1 receptor antagonist in traps. , 2004, The American journal of medicine.

[248]  X. Mariette,et al.  Tumour necrosis factor α blocking agents in refractory adult Still’s disease: an observational study of 20 cases , 2004 .

[249]  B. Manger,et al.  Langzeitergebnisse einer TNF-Blockade beim Morbus Still im Erwachsenenalter , 2004 .

[250]  Polly Matzinger,et al.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.

[251]  I. Foeldvari,et al.  The German etanercept registry for treatment of juvenile idiopathic arthritis , 2004, Annals of the rheumatic diseases.

[252]  F. Martinon,et al.  NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. , 2004, Immunity.

[253]  N. Katsilambros,et al.  Successful treatment of refractory adult-onset Still’s disease with infliximab. A prospective, non-comparative series of four patients , 2004, Clinical Rheumatology.

[254]  D. Kastner,et al.  Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[255]  R. Terkeltaub.  Clinical practice. Gout. , 2003, The New England journal of medicine.

[256]  James E. Evans,et al.  Molecular identification of a danger signal that alerts the immune system to dying cells , 2003, Nature.

[257]  G. Hitman,et al.  Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. , 2003, Arthritis and rheumatism.

[258]  D. Kastner,et al.  Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. , 2003, Arthritis and rheumatism.

[259]  P. Hawkins,et al.  Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. , 2003, The New England journal of medicine.

[260]  H. Waterham,et al.  Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept , 2002, Clinical and experimental immunology.

[261]  E. Remmers,et al.  De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. , 2002, Arthritis and rheumatism.

[262]  Joachim Sieper,et al.  Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches , 2002, Arthritis research.

[263]  P. Bowness.  HLA B27 in health and disease: a double-edged sword? , 2002, Rheumatology.

[264]  F. Martinon,et al.  The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. , 2002, Molecular cell.

[265]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[266]  A. Fischer,et al.  Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. , 2002, American journal of human genetics.

[267]  Y. Molad.  Update on colchicine and its mechanism of action , 2002, Current rheumatology reports.

[268]  M. Weinblatt,et al.  Etanercept in the treatment of adult patients with Still's disease. , 2002, Arthritis and rheumatism.

[269]  Stanley B. Cohen,et al.  Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[270]  J. Drenth,et al.  Hereditary periodic fever. , 2001, The New England journal of medicine.

[271]  C. Antoni,et al.  Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences , 2001, Annals of the rheumatic diseases.

[272]  R. Kolodner,et al.  Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome , 2001, Nature Genetics.

[273]  D. Broide,et al.  Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. , 2001, The Journal of allergy and clinical immunology.

[274]  L. Lovat,et al.  Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein , 2001, The Lancet.

[275]  M. Harding,et al.  ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs , 2001, Expert opinion on investigational drugs.

[276]  D. Lipsker,et al.  The Schnitzler Syndrome: Four New Cases and Review of the Literature , 2001, Medicine.

[277]  A. Bowcock,et al.  Localization of a gene for familial recurrent arthritis. , 2000, Arthritis and rheumatism.

[278]  J. Seidman,et al.  Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q. , 2000, American journal of human genetics.

[279]  H. Waterham,et al.  Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome , 1999, Nature Genetics.

[280]  Joost P.H. Drenth,et al.  Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome , 1999, Nature Genetics.

[281]  Ian Todd,et al.  Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes , 1999, Cell.

[282]  E. Ben-Chetrit,et al.  Colchicine: 1998 update. , 1998, Seminars in arthritis and rheumatism.

[283]  C. Janeway,et al.  Innate Immunity: The Virtues of a Nonclonal System of Recognition , 1997, Cell.

[284]  Jacques Demaille,et al.  A candidate gene for familial Mediterranean fever , 1997, Nature Genetics.

[285]  F. Collins,et al.  Ancient Missense Mutations in a New Member of the RoRet Gene Family Are Likely to Cause Familial Mediterranean Fever , 1997, Cell.

[286]  C. Seidman,et al.  A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. , 1997, Mayo Clinic proceedings.

[287]  K. Edwards,et al.  Periodic fever syndrome in children. , 1994, The Journal of pediatrics.

[288]  A. Martini,et al.  Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[289]  D. Zemer,et al.  Long-term colchicine treatment in children with familial Mediterranean fever. , 1991, Arthritis and rheumatism.

[290]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor , 1990, Nature.

[291]  C. Janeway,et al.  Immunogenicity signals 1,2,3 ... and 0. , 1989, Immunology today.

[292]  J. Dayer,et al.  Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). , 1986, The Journal of clinical investigation.

[293]  J. Nerup,et al.  Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. , 1986, Science.

[294]  B. Beutler,et al.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1 , 1986, The Journal of experimental medicine.

[295]  E. Blau.  Familial granulomatous arthritis, iritis, and rash. , 1985, The Journal of pediatrics.

[296]  F. Arnett,et al.  Familial granulomatous synovitis, uveitis, and cranial neuropathies. , 1985, The American journal of medicine.

[297]  D. Alling,et al.  Colchicine therapy for familial mediterranean fever. A double-blind trial. , 1974, The New England journal of medicine.

[298]  L. Stamp,et al.  Gout and its comorbidities: implications for therapy. , 2013, Rheumatology.

[299]  H. Boysson,et al.  Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence , 2012, Clinical Rheumatology.

[300]  T. Heike,et al.  [Hyperimmunoglobulinemia D and periodic fever syndrome]. , 2011, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology.

[301]  M. Yashiro,et al.  Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: its possible action and mechanism. , 2010, Arthritis and rheumatism.

[302]  C. Bodemer,et al.  Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. , 2010, Arthritis and rheumatism.

[303]  K. Papp.  Monitoring patients treated with efalizumab or alefacept. , 2009, Current problems in dermatology.

[304]  J. D. Edgar,et al.  Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome , 2009, Rheumatology International.

[305]  J. G. Ryan,et al.  IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. , 2008, The Journal of allergy and clinical immunology.

[306]  M. Bours,et al.  Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. , 2006, Pharmacology & therapeutics.

[307]  M. Zeier,et al.  Successful treatment of chronic tophaceous gout with infliximab (Remicade) , 2005, Rheumatology International.

[308]  K. Bendtzen,et al.  TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. , 2004, Clinical and experimental rheumatology.

[309]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[310]  A. So,et al.  Extended Report , 2022 .

[311]  D. Foell,et al.  Extended Report , 2022 .